Recombinant human interleukin-2 for injection

This product is a lymphokine that can proliferate cytotoxic T cells, natural killer cells and lymphokine-activated killer cells and enhance their killing activity. It can also promote lymphocytes to secrete antibodies and interferons, and has anti-viral, anti-tumor and immune enhancement effects. Long-term toxicity tests on animals have shown that no abnormalities were found in blood picture, blood and urine biochemical tests, circulatory system examinations, and pathological tissue examinations.

Main ingredients: recombinant human interleukin-2, derived from recombinant Escherichia coli; auxiliary materials: human albumin.

White or slightly yellow loose body, easily soluble in water, after dissolution it becomes clear liquid, with no insoluble matter visible to the naked eye.

1. It is used for the treatment of malignant tumors such as renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, rectal cancer, lymphoma, lung cancer, etc. It is used for the control of cancerous pleural effusion and ascites, and can also be used for the cultivation of lymphokine-activated killer cells. 2. It is used for the treatment of tumor patients after surgery, radiotherapy and chemotherapy to enhance the body's immune function. 3. It is used for the treatment of congenital or acquired immunodeficiency to improve the patient's cellular immune function and anti-infection ability. 4. The treatment of various autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, etc. 5. It has a certain therapeutic effect on certain viral and bacillary diseases, and intracellular parasitic infectious diseases, such as hepatitis B, leprosy, tuberculosis, and Candida albicans infection.

This product should be used under the guidance of a clinical physician. The specific usage, dosage and course of treatment vary from disease to disease. The following routine usage is recommended. 1. Systemic administration: ① Intravenous infusion: Recombinant human interleukin-2.2 million IU/m2 (equivalent to 300,000 IU/time for adults) is added to 100-500 ml of sterile saline, infused for 2-3 hours, once a day, and a course of 4-6 weeks. ② Intramuscular injection: Recombinant human interleukin-2.2 million-400,000 IU/m2 is dissolved in 2 ml of sterile saline, and injected intramuscularly 2-3 times/week, and a course of 4-6 weeks. 2. Regional and local administration: ① Pleural injection: For cancerous pleural effusion, try to remove the effusion in the cavity and then inject recombinant human interleukin-2.2 million IU/m2 (equivalent to 300,000 IU/time for adults), 1-2 times/week, and a course of 2-4 weeks (or the effusion disappears). ② Arterial perfusion or local administration to tumor lesions: limited to research and observation by oncologists.

The most common adverse reactions are fever and chills, which are related to the dosage. Generally, it is a transient fever (around 38°C), and there may also be chills and high fever. The body temperature can return to normal 3-4 hours after stopping the drug. Some patients may experience nausea, vomiting, and cold-like symptoms. Mild redness, swelling, nodules, and pain may occur locally after subcutaneous injection. All side effects can recover on their own after stopping the drug. When using a larger dose, this product may cause capillary leak syndrome, which manifests as hypotension, peripheral edema, temporary renal insufficiency, etc. The safe dose should be strictly controlled when using this product, and symptomatic treatment can be given if the above reactions occur.

1. Patients with a history of allergy to the ingredients of this product. 2. Patients with high fever, severe heart disease, hypotension, severe heart and kidney failure, abnormal lung function or those who have undergone organ transplantation. 3. Recombinant human interleukin-2 has had toxic reactions related to it in the past: (1) Sustained ventricular tachycardia. (2) Uncontrolled arrhythmia. (3) Chest pain accompanied by electrocardiographic changes, angina pectoris or myocardial infarction. (4) Cardiac tamponade. (5) Renal failure requiring dialysis for more than 72 hours. (6) Coma or toxic psychosis for more than 48 hours. (7) Intractable or intractable epilepsy. (8) Local intestinal ischemia or perforation. (9) Gastrointestinal bleeding requiring surgical operation. (10) Use with caution in pregnant women.

Precautions for children: This product has not been tested and there is no reliable reference. Precautions for pregnancy and lactation: Use with caution in pregnant and lactating women. Precautions for the elderly: This product has not been tested and there is no reliable reference.

This product has not been tested and there is no reliable reference.

Store and transport at 2-8℃ away from light.

1 million IU/bottle

30 months

Changchun Lnstitute of Biological Products Co., Ltd.

• Founded in:

  1985-12-05

• Address:

  No. 1616, Chuangxin Road, Changchun High-tech Development Zone (Production and operation location: No. 285, Chaoran Street, Changchun High-tech Development Zone)

• Tax NO.:

  91220101123998130E

• Registered Funds:

  2,094.3041 million yuan

• Website:

  Log in to view

• Email:

  Log in to view